|
DE19911509A1
(de)
|
1999-03-15 |
2000-09-21 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
DE10042058A1
(de)
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
WO2005026150A1
(en)
|
2003-09-16 |
2005-03-24 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
|
DE10349113A1
(de)
|
2003-10-17 |
2005-05-12 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von Aminocrotonylverbindungen
|
|
MX2007009265A
(es)
|
2005-02-04 |
2007-09-07 |
Boehringer Ingelheim Int |
Uso de inhibidores de tirosina quinasa para el tratamiento de rinosinusitis cronica.
|
|
CA2601936C
(en)
|
2005-02-24 |
2014-06-17 |
Amgen Inc. |
Epidermal growth factor receptor mutations
|
|
CN101351563A
(zh)
|
2005-10-05 |
2009-01-21 |
阿斯利康(英国)有限公司 |
用于预测或监测病人对于ErbB受体药物的响应的方法
|
|
TWI377944B
(en)
|
2007-06-05 |
2012-12-01 |
Hanmi Holdings Co Ltd |
Novel amide derivative for inhibiting the growth of cancer cells
|
|
PE20100252A1
(es)
|
2008-06-06 |
2010-04-12 |
Boehringer Ingelheim Int |
Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
|
|
KR101217526B1
(ko)
*
|
2010-06-11 |
2013-01-02 |
한미사이언스 주식회사 |
아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
|
|
US8828391B2
(en)
|
2011-05-17 |
2014-09-09 |
Boehringer Ingelheim International Gmbh |
Method for EGFR directed combination treatment of non-small cell lung cancer
|
|
KR101317809B1
(ko)
|
2011-06-07 |
2013-10-16 |
한미약품 주식회사 |
암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
|
|
US9738935B2
(en)
|
2011-11-10 |
2017-08-22 |
Roche Molecular Systems, Inc. |
Complex mutations in the epidermal growth factor receptor kinase domain
|
|
EP3603678A3
(en)
*
|
2011-12-14 |
2020-07-29 |
The Board of Regents of the University of Texas System |
Collateral gene inactivation biomarkers and targets for cancer therapy
|
|
AU2013355260B2
(en)
|
2012-12-04 |
2019-07-25 |
Caris Mpi, Inc. |
Molecular profiling for cancer
|
|
US20180057603A1
(en)
|
2013-08-09 |
2018-03-01 |
The Trustees Of The University Of Pennsylvania |
Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
|
|
TWI603971B
(zh)
|
2013-08-22 |
2017-11-01 |
Taiho Pharmaceutical Co Ltd |
Novel quinoline substituted compounds
|
|
EP3699589A1
(en)
|
2014-12-12 |
2020-08-26 |
Celcuity Inc. |
Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients
|
|
CN107250108B
(zh)
|
2015-02-05 |
2020-11-27 |
特尔诺沃有限公司 |
用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
|
|
CN107530434A
(zh)
|
2015-04-23 |
2018-01-02 |
免疫医疗有限公司 |
非小细胞肺癌egfr突变阳性的联合疗法
|
|
US10308658B2
(en)
|
2015-10-19 |
2019-06-04 |
Sunshine Lake Pharma Co., Ltd. |
Salt of EGFR inhibitor, crystalline form and uses thereof
|
|
EP3458064A1
(en)
|
2016-05-18 |
2019-03-27 |
Boehringer Ingelheim International GmbH |
Anticancer combination therapy
|
|
CN109789204A
(zh)
*
|
2016-05-31 |
2019-05-21 |
雀巢产品技术援助有限公司 |
基于her2和her3通路亚型选择乳癌患者药物疗法的方法
|
|
BR112019010020A2
(pt)
|
2016-11-17 |
2019-08-20 |
Univ Texas |
compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
|
|
EP3585389A4
(en)
|
2017-02-22 |
2020-12-23 |
G1 Therapeutics, Inc. |
EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
|
|
WO2018213770A1
(en)
|
2017-05-19 |
2018-11-22 |
Regents Of The University Of Minnesota |
Therapeutic methods
|
|
CA3076915A1
(en)
|
2017-09-27 |
2019-04-04 |
AI Therapeutics, Inc. |
Therapeutic methods relating to hsp90 inhibitors
|
|
KR20190054826A
(ko)
|
2017-11-14 |
2019-05-22 |
한미약품 주식회사 |
암의 포지오티닙 치료에 대한 반응을 나타내는 바이오마커 및 그의 용도
|
|
JP7386174B2
(ja)
|
2018-03-27 |
2023-11-24 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
Her2エクソン19変異を有するがん細胞に対する抗腫瘍活性を有する化合物
|
|
US20210235688A1
(en)
|
2018-04-19 |
2021-08-05 |
Board Of Regents, The University Of Texas System |
Methods for measuring and stabilizing stat3 inhibitors
|
|
SG11202012064PA
(en)
|
2018-06-25 |
2021-01-28 |
Spectrum Pharmaceuticals Inc |
Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
|
|
CA3098204A1
(en)
|
2018-06-25 |
2020-01-02 |
Spectrum Pharmaceuticals, Inc. |
Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
|
|
KR20210066819A
(ko)
|
2018-09-04 |
2021-06-07 |
레인 세러퓨틱스 인코포레이티드 |
Her-유도 암을 치료 또는 예방하기 위한 화합물, 조성물 및 방법
|
|
KR20210107023A
(ko)
*
|
2018-12-21 |
2021-08-31 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
암 치료를 위한 조합 요법
|
|
WO2020150208A1
(en)
|
2019-01-14 |
2020-07-23 |
Board Of Regents, The University Of Texas System |
Compositions and methods for treating cancer using il-17 signaling inhibitors and immune checkpoint inhibitors
|
|
US12679855B2
(en)
|
2019-01-27 |
2026-07-14 |
Board Of Regents, The University Of Texas System |
Inhibitors of the enzyme enolase for precision oncology
|
|
WO2020172485A1
(en)
|
2019-02-22 |
2020-08-27 |
Board Of Regents, The University Of Texas System |
Methods of using imipridones
|
|
MX2021010265A
(es)
|
2019-02-26 |
2021-09-23 |
Janssen Biotech Inc |
Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
|
|
US20200299783A1
(en)
|
2019-03-18 |
2020-09-24 |
Board Of Regents, The University Of Texas System |
Molecular signature for selecting lymphoma patients for treatment with ibrutinib
|
|
WO2020198633A1
(en)
|
2019-03-27 |
2020-10-01 |
Board Of Regents, The University Of Texas System |
Nuclear-derived exosomes and methods of use thereof
|
|
WO2020205646A2
(en)
|
2019-03-29 |
2020-10-08 |
Board Of Regents, The University Of Texas System |
Small molecule parg inhibitors and methods of use thereof
|
|
US12629375B2
(en)
|
2019-03-29 |
2026-05-19 |
Board Of Regents, The University Of Texas System |
Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions
|
|
US20220143023A1
(en)
|
2019-03-29 |
2022-05-12 |
Board Of Regents, The University Of Texas System |
Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
|
|
JP7709384B2
(ja)
|
2019-04-17 |
2025-07-16 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
チロシンキナーゼ阻害剤耐性egfr変異を有するがんに対する化合物
|
|
JP7822597B2
(ja)
|
2019-04-17 |
2026-03-03 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
チロシンキナーゼ阻害剤耐性egfr変異を有するがん細胞に対する抗腫瘍活性を有する化合物
|
|
KR102477643B1
(ko)
*
|
2019-05-09 |
2022-12-13 |
주식회사 엘지에너지솔루션 |
전기화학소자용 분리막 및 이를 포함하는 전기화학소자
|
|
WO2020251965A1
(en)
|
2019-06-10 |
2020-12-17 |
Board Of Regents, The University Of Texas System |
Combinatorial therapy targeting parp1 and rtk
|
|
US20220356467A1
(en)
|
2019-06-25 |
2022-11-10 |
Board Of Regents, The University Of Texas System |
Methods for duplex sequencing of cell-free dna and applications thereof
|